Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR

The introduction of imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia. Even though experience with imatinib mesylate is limited, clinical resistance has already been observed In order to overcome imatinib resistance, more potent tyrosine kinase inhibitors such as nilotinib and dasatinib have been developed, with demonstrable activity against most BCR-ABL domain mutations with the notable exception of T315I mutation. Moreover, with the increased use of newer tyrosine kinase inhibitors it has been suggested that the spectrum of mutations may change, possibly selecting the pan-resistant T315I. That is why mutational analysis should be done on a regular basis or at any time the clinical and hematological aspects change, in order to give the patient the best therapy available.